Vepdegestrant Wins FDA Approval, Bringing Protein Degradation Drugs to the Front Line of Breast Cancer Treatment

Many cancer drugs aim to quiet dangerous signals. The shift brought by vepdegestrant goes a step further: it asks cells to “dismantle” the target protein. The U.S. Food and Drug Administration’s approval of this oral drug for certain advanced or metastatic breast cancers is meaningful not only because it adds another treatment option, but also because protein degradation therapy has finally crossed a regulatory threshold and entered the everyday clinical vocabulary of cancer care.

On May 1, 2026, the FDA approved vepdegestrant, marketed under the brand name Veppanu, for adults with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations. Eligible patients must have experienced disease progression after at least one line of endocrine therapy. The FDA also approved Guardant360 CDx as a companion diagnostic to identify whether tumors carry ESR1 mutations, underscoring that this treatment depends from the outset on molecular testing to select patients.

This type of breast cancer has long relied on endocrine therapy, because cancer cell growth is often driven by the estrogen receptor. Under treatment pressure, however, ESR1 gene mutations may keep the receptor active even without estrogen stimulation, causing drugs that were once effective to gradually lose their effect. Vepdegestrant’s strategy is to use PROTAC protein degradation technology to bring the estrogen receptor close to the cell’s ubiquitin-proteasome system, prompting the receptor to be tagged and broken down.

The FDA review was based on the VERITAC-2 trial, which enrolled 624 adults with ER-positive, HER2-negative advanced or metastatic breast cancer, including 270 whose tumors carried ESR1 mutations. All participants had previously worsened after one to two lines of endocrine therapy and included patients who had received CDK4/6 inhibitors. The trial compared daily oral vepdegestrant with intramuscular fulvestrant.

In the ESR1-mutant population, vepdegestrant achieved a median progression-free survival of 5 months, compared with 2.1 months for fulvestrant in the control group. Objective response rates were 19% and 4%, respectively. These figures show that it does have clinical benefit, but the scale of that benefit should still be understood in the reality of advanced, previously treated patients: this is not a curative breakthrough, but a way to extend the period of disease control for a group of patients selected through molecular testing after resistance has emerged.

The limitations are also clear. FDA data show that overall survival data were not yet mature at the time of the progression-free survival analysis. The label also lists warnings including QTc interval prolongation and embryo-fetal toxicity. In other words, this approval confirms the drug’s benefit in a specific biomarker-defined population, but it has not yet answered whether it can extend life, how it should be sequenced with existing targeted therapies, or whether it is similarly appropriate at earlier stages of treatment.

The real change may lie in the treatment paradigm. In the past, anticancer drugs mostly tried to inhibit enzyme activity or block receptor signaling. PROTAC instead turns the cell’s own protein clearance mechanism into a drug tool. Vepdegestrant’s approval will not automatically make this platform applicable to all cancers, but it provides an important clinical precedent: when a cancer-driving protein is difficult to switch off through conventional means, directly causing it to disappear is becoming a treatment path that can be regulated, tested, and actually used by patients.